Transferring Phosphorus Containing Group (e.g., Kineases, Etc.(2.7)) Patents (Class 435/194)
  • Publication number: 20110224106
    Abstract: A method is provided for generating single stranded circular nucleic acid from a sample of target nucleic acid. A complex comprising a transposase and a plurality of hairpin polynucleotides is formed with each of the hairpin polynucleotides having a duplex region comprising a transposase recognition sequence. The complex is mixed with the target nucleic acid, thereby fragmenting the target nucleic acid and ligating the hairpin polynucleotides to the target nucleic acid to form hairpin-linked nucleic acid fragments, each having a nucleobase segment gap between each fragment and its corresponding hairpin polynucleotide. The hairpin-linked fragments are contacted with a ligase, thereby ligating the hairpin-linked fragments together to form single-stranded circular nucleic acid comprising a pair of opposing loops and an intervening duplex region comprising a pair of nucleobase segment gaps.
    Type: Application
    Filed: March 9, 2011
    Publication date: September 15, 2011
    Applicant: Ibis Biosciences, Inc.
    Inventors: Mark W. Eshoo, John Picuri
  • Publication number: 20110224105
    Abstract: Methods, kits, and compositions are provided herein for the generation of double stranded DNA products suitable for downstream analysis.
    Type: Application
    Filed: August 12, 2010
    Publication date: September 15, 2011
    Applicant: NuGEN Technologies, Inc.
    Inventors: Nurith Kurn, Shenglong Wang
  • Publication number: 20110217737
    Abstract: Chimeric proteins comprising a sequence nonspecific single-stranded nucleic-acid-binding domain joined to a catalytic nucleic-acid-modifying domain are provided. Methods comprising contacting a nucleic acid molecule with a chimeric protein, as well as systems comprising a nucleic acid molecule, a chimeric protein, and an aqueous solution are also provided. The joining of sequence nonspecific single-stranded nucleic-acid-binding domain and a catalytic nucleic-acid-modifying domain in chimeric proteins, among other things, may prevent the separation of the two domains due to their weak association and thereby enhances processivity while maintaining fidelity.
    Type: Application
    Filed: November 27, 2007
    Publication date: September 8, 2011
    Inventors: Yousif Shamoo, Siyang Sun
  • Publication number: 20110217735
    Abstract: The present invention is directed to compositions and methods useful for the amplification of nucleic acid molecules by reverse transcriptase-polymerase chain reaction (RT-PCR). Specifically, the invention provides compositions and methods for the amplification of nucleic acid molecules in a simplified one- or two-step RT-PCR procedure using combinations of reverse transcriptase and thermostable DNA polymerase enzymes in conjunction with sulfur-containing molecules or acetate-containing molecules (or combinations of such sulfur-containing molecules and acetate-containing molecules), and optionally bovine serum albumin. The invention thus facilitates the rapid and efficient amplification of nucleic acid molecules and the detection and quantitation of RNA molecules. The invention also is useful in the rapid production and amplification of cDNAs which may be used for a variety of industrial, medical and forensic purposes.
    Type: Application
    Filed: December 29, 2010
    Publication date: September 8, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Jun E. Lee, Ayoub Rashtchian
  • Publication number: 20110217736
    Abstract: System, including methods, apparatus, compositions, and kits, for making and using compound droplets of a multiple emulsion to supply an amplification reagent, such as a heat-stable DNA polymerase or DNA ligase, to an aqueous phase in which the compound droplets are disposed. The compound droplets may be induced to supply the amplification reagent by heating the multiple emulsion, to achieve hot-start amplification.
    Type: Application
    Filed: March 2, 2011
    Publication date: September 8, 2011
    Applicant: QUANTALIFE, INC.
    Inventor: Benjamin J. HINDSON
  • Patent number: 8013114
    Abstract: The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: September 6, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventor: Vikas Kundra
  • Publication number: 20110212133
    Abstract: The present invention relates to novel diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by Pseudomonas aeruginosa, and conditions associated with such infections, such as, for example, an acute clinical exacerbation in a cystic fibrosis (CF) subject. In particular, the present invention relates to methods for diagnosing/prognosing an infection by P. aeruginosa in a subject comprising detecting the presence or amount of one or more proteins of P. aeruginosa or a fragment or epitope thereof or an antibody thereto in a sample from the subject.
    Type: Application
    Filed: February 3, 2011
    Publication date: September 1, 2011
    Inventors: Andrew John Sloane, Susanne Kartin Pedersen, Ron Weinberger
  • Patent number: 8008054
    Abstract: A purified thermostable enzyme is derived form the thermophilic archaebacterium Thermococcus gorgonarius. The enzyme can be native or recombinant, retains approximately 90% of its activity after incubation for two hours at 95° C. in the presence of stabilizing agents and possesses 3?-5? proofreading exonuclease activity. Thermostable DNA polymerases are useful in many recombinant DNA techniques, especially nucleic acid amplification by the polymerase chain reaction (PCR).
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 30, 2011
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Waltraud Ankenbauer, Vitaly Svetlichny, Elizaveta Bonch-Osmolovskaya, Christine Ebenbichler, Bernhard Angerer, Gudrun Schmitz-Agheguian, Frank Laue
  • Patent number: 8008053
    Abstract: A method of altering the conformation of a polypeptide having a known three-dimensional structure is described. The method comprises attaching a first end of a polymer to a first portion of the polypeptide, attaching a second end of the polymer to a second portion of the polypeptide, and altering the mechanical tension of the polymer, thereby altering the conformation of the polypeptide. The alteration of the conformation of the polypeptide may increase or decrease the binding affinity of the polypeptide for a substrate bound by the polypeptide, or alter the catalytic rate of an enzyme. Typically, the polymer is a polynucleotide or polypeptide.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: August 30, 2011
    Assignee: The Regents of the University of California
    Inventors: Giovanni Zocchi, Brian Choi
  • Publication number: 20110207676
    Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.
    Type: Application
    Filed: April 27, 2011
    Publication date: August 25, 2011
    Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
  • Publication number: 20110207631
    Abstract: A method for efficiently constructing a cDNA library having a reduced content of cDNA clones derived from a highly expressed gene is provided. According to the method for constructing a cDNA library using a double-stranded DNA primer having oligo dT and mRNA as a template, the proportion of cDNA clones derived from a highly expressed gene in a cDNA library was decreased through coexistence with a probe having a property of binding to the mRNA of the highly expressed target gene so as to inhibit a cDNA extension reaction resulting from reverse transcriptase.
    Type: Application
    Filed: August 25, 2009
    Publication date: August 25, 2011
    Inventors: Kuniyo Ohtoko, Masahide Sugiyama, Seishi Kato
  • Patent number: 8002891
    Abstract: The present invention relates to molecules and molecular complexes which comprise the active site binding pockets of JNK3 or close structural homologues of the active site binding pockets.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: August 23, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Xiaoling Xie, Yong Gu, William Markland, Michael S. Su, Paul R. Caron, Edward Fox, Keith P. Wilson
  • Publication number: 20110201010
    Abstract: The present invention provides compositions, methods, and kits relating to the protection and deprotection of molecules comprising nucleophilic groups, such as the protection and deprotection of thermostable polymerases. Also provided are methods of performing nucleic acid amplification using polymerases protected according to the invention.
    Type: Application
    Filed: July 2, 2009
    Publication date: August 18, 2011
    Inventors: Fei Mao, Xing Xin, Wai-Lee Leung
  • Patent number: 7999073
    Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: August 16, 2011
    Assignee: Lonza Cologne GmbH
    Inventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Grabek, Andrea Mueller-Hartmann
  • Patent number: 7998718
    Abstract: A novel S6 kinase, p70?S6k is described, along with methods of making and using p70?S6k protein and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70?S6k protein and/or its ligands.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: August 16, 2011
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Ivan Gout, Kenta Hara, Mike Waterfield, Kazu Yonezawa
  • Patent number: 7999075
    Abstract: A method of screening a candidate compound for ?Arrestin mediated anti-G protein coupled receptor signaling activity is comprises: (a) contacting said candidate compound to a ?Arrestin signaling complex or a constituent thereof, under conditions in which a signaling complex is formed; and then (b) detecting the presence or absence of disruption of said signaling complex, disruption of said complex indicating said compound has ?Arrestin mediated anti-G protein coupled receptor signaling activity. Compositions and kits for carrying out the method are also described.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: August 16, 2011
    Assignee: Duke University
    Inventors: Marc G. Caron, Martin Beaulieu, Raul R. Gainetdinov, Tatiana D. Sotnikova, Sébastien Marion
  • Publication number: 20110195478
    Abstract: The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.
    Type: Application
    Filed: August 4, 2010
    Publication date: August 11, 2011
    Inventors: Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang
  • Publication number: 20110195457
    Abstract: Methods and kits for amplifying a nucleic acid under isothermal conditions to form an amplified nucleic acid sequence are provided. The methods and kits comprises providing a nucleic acid template, a DNA polymerase, deoxyribonucleoside triphosphates, a primer comprising a randomized sequence, and a specific primer, and amplifying the nucleic acid template.
    Type: Application
    Filed: February 9, 2010
    Publication date: August 11, 2011
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: John Richard Nelson, Wei Gao, Ming Zhao
  • Publication number: 20110195479
    Abstract: The invention relates to thermostable polymerases that have polymerase activity temperatures in the range from 90.degree. C. up to 113.degree. C., such as those derived from Pyrolobus fumaria, and to polynucleotides encoding the polymerases In addition, methods of designing new thermostable DNA polymerases and methods of use thereof are also provided. The polymerases have increased activity and stability at increased pH and temperature.
    Type: Application
    Filed: July 2, 2010
    Publication date: August 11, 2011
    Applicant: VERENIUM CORPORATION
    Inventors: WALTER CALLEN, ERIC J. MATHUR
  • Publication number: 20110195405
    Abstract: Compositions, methods, and kits for reducing strand amplification bias using bisulfite treated gDNA are provided. Methods for detecting and for quantitating the amplified bisulfite treated gDNA and inferring the presence, absence, and/or degree of methylation of target cytosine(s) in the gDNA are also provided. Such methods typically employ tailed first primer pairs, which can, but need not comprise nucleotide analogs, and optionally second primer pairs.
    Type: Application
    Filed: December 7, 2010
    Publication date: August 11, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventor: Victoria L. BOYD
  • Publication number: 20110195406
    Abstract: Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period.
    Type: Application
    Filed: December 30, 2010
    Publication date: August 11, 2011
    Applicant: Pacific Biosciences of California, Inc.
    Inventors: Jon Sorenson, Ali Bashir, Fred Christians, Stephen Turner, Eric C. Olivares, Jason Underwood
  • Patent number: 7993841
    Abstract: A polynucleotide consisting of the base sequence of SEQ ID NO: 2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at the least 10 consecutive nucleotides, and finally use of the probe for proving parkinsonism inheritance.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 9, 2011
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Jan O Aasly, Zbigniew K Wszolek, Matthew J Farrer
  • Publication number: 20110191898
    Abstract: Threonine is an essential amino acid for humans and in the animal feed industry where its levels in feed rations can significantly impact the cost of production of important meat sources, such as swine and poultry. Threonine as well as essential amino acids lysine and methionine are all synthesized via the aspartate family pathway. Aspartate kinase (AK) is the first enzyme in the pathway, and catalyzes the ATP-dependent phosphorylation of aspartate to form ?-aspartyl phosphate. AK constitutes the main regulatory step controlling the metabolic flux through the pathway, and is subject to end product inhibition by Lys and/or Thr. The current invention provides a method to produce a transgenic high free threonine soybean via the overexpression of feed-back-resistant AK enzymes in developing soybean plants and seeds. These modifications provide a method to enhance both plant nitrogen metabolism and crop growth performance.
    Type: Application
    Filed: June 30, 2009
    Publication date: August 4, 2011
    Applicant: Monsanto Technology LLC
    Inventors: James H. Crowley, Barry S. Goldman, Jintai Huang, Qungang Qi, Willam D. Rapp
  • Publication number: 20110189659
    Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions and/or heterologous or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties can include reduced reaction rates at one or more steps of the polymerase kinetic cycle, increased closed polymerase/DNA complex stability, enhanced metal ion coordination, reduced exonuclease activity, decreased branching fractions, and the like. Polymerases that exhibit branching fractions that are less than the branching fractions of the polymerases from which they were derived, or branching fractions that are less than about 25% for a phosphate-labeled nucleotide analog, are also provided. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.
    Type: Application
    Filed: September 30, 2010
    Publication date: August 4, 2011
    Applicant: Pacific Biosciences of California, Inc.
    Inventors: Sonya Clark, Arek Bibillo, Paul Peluso, Fred Christians, Molly He, Insil Park, Harold Lee, Keith Bjornson, Lei Jia, Robin Emig
  • Publication number: 20110189688
    Abstract: The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumours of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics.
    Type: Application
    Filed: December 2, 2010
    Publication date: August 4, 2011
    Inventors: Mike Stratton, Andy Futreal, Richard Wooster, Richard Malcolm Marais, Chris Marshall
  • Publication number: 20110189155
    Abstract: Use of the large form of human 2?,5?-Oligoadenylate Synthetase (OAS3) for diagnosis, prevention and treatment of infection with positive-sense single-stranded RNA viruses and for prediction of human genetic susceptibility to positive-sense single-stranded RNA virus-related diseases.
    Type: Application
    Filed: May 20, 2009
    Publication date: August 4, 2011
    Inventors: Anne-Claire Brehin, Anavaj Sakuntabhai, Philippe Despres, Isabelle Casademont, Cécile Julier, Ampaiwan Chuansumrit, Prida Malasit, Sylvie Paulous
  • Publication number: 20110178182
    Abstract: A method of producing a nanostructure composition from a solid powder is disclosed. The method comprises: (a) heating the solid powder, thereby providing a heated solid powder; (b) immersing the heated solid powder in a liquid in the presence of a gas medium, the liquid being colder than the heated powder, and (c) irradiating the cold liquid, the heated solid powder and the gas medium by electromagnetic radiation selected such that nanostructures are formed from particles of the solid powder and a stable gas phase is formed from the gas medium.
    Type: Application
    Filed: August 20, 2008
    Publication date: July 21, 2011
    Inventor: Eran Gabbai
  • Publication number: 20110177568
    Abstract: The present invention relates to a method of microbial production of L-lysine from methanol and other substrates, and particularly improving the production of L-lysine from such substrates. The invention concerns a method for producing lysine in B. methanolicus, said method comprising overexpressing an aspartate kinase III (AKIII) enzyme in said B. methanolicus. In particular the method may concern introducing a nucleic acid molecule comprising a nucleotide sequence encoding an AKIII enzyme into a B. methanolicus. The invention also relates to a B. methanolicus micro-organism which overexpresses an AKIII enzyme, nucleic acid molecules which encode polypeptides having AK activity, polypeptides which have AK activity and host cells and vector systems comprising the nucleic acid molecules or vector.
    Type: Application
    Filed: May 20, 2009
    Publication date: July 21, 2011
    Inventors: Trygve Brautaset, Øyvind Mejdell Jakobsen, Trond Ellingsen
  • Publication number: 20110177539
    Abstract: A biological process indicator is provided for validating a treatment process in which the amount or activity of a contaminant in a sample is reduced. The indicator comprises a thermostable kinase covalently linked to a biological component, with the proviso that the biological component is not an antibody. Methods of preparing the indicator, and methods of using the indicator, are also provided.
    Type: Application
    Filed: February 18, 2009
    Publication date: July 21, 2011
    Applicant: HEALTH PROTECTION AGENCY
    Inventors: J. Mark Sutton, J. Richard Hesp, Michael Ungurs
  • Publication number: 20110177497
    Abstract: The invention provides novel nucleic acid polymerases from strains GK24 and RQ-1 of Thermus thermophilus, and nucleic acids encoding those polymerases, as well as methods for using the polymerases and nucleic acids.
    Type: Application
    Filed: October 14, 2010
    Publication date: July 21, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: James E. Rozzelle, Elena BOLCHAKOVA
  • Publication number: 20110171714
    Abstract: The invention relates to molecules or molecular complexes which comprise binding pockets of TAK1 or its structural homologues. The invention relates to crystallizable compositions and crystals comprising TAK1. The present invention also relates to a data storage medium encoded with the structural coordinates of molecules and molecular complexes which comprise the TAK1 or TAK1-like ATP-binding pockets. The present invention also relates to a computer comprising such data storage material. The computer may generate a three-dimensional structure or graphical three-dimensional representation of such molecules or molecular complexes. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to TAK1 or homologues thereof.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Graham Cheetham, Kieron Brown, Sarah Vial, Neesha Dedi
  • Publication number: 20110171717
    Abstract: A polymerase activity is effectively enhanced by adding an anionic surfactant, in particular an anionic surfactant having a polyethoxyl group, to a reaction mixture containing a polymerase.
    Type: Application
    Filed: November 26, 2010
    Publication date: July 14, 2011
    Inventors: Eiji KOBAYASHI, Yuki UEDA, Yoshimi SATO, Takashi UEMORI, Hiroyuki MUKAI, Ikunoshin KATO
  • Patent number: 7977077
    Abstract: Enzymatic pathways for production of aminoshikimate, kanosamine, intermediates, and derivatives thereof; nucleic acid encoding and cells containing the enzymes; compositions containing aminoshikimate, kanosamine, an intermediate or derivative thereof; and use of the cells and pathways for biosynthetic production of aminoshikimate, kanosamine, intermediates, and derivatives thereof.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: July 12, 2011
    Assignee: Board of Trustees of Michigan State University
    Inventors: John W. Frost, Jiantao Guo
  • Publication number: 20110165654
    Abstract: This invention provides for an improved generation of novel nucleic acid modifying enzymes. The improvement is the fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.
    Type: Application
    Filed: March 14, 2011
    Publication date: July 7, 2011
    Applicant: Bio-Rad Laboratories, Inc.
    Inventor: Yan Wang
  • Publication number: 20110165596
    Abstract: The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.
    Type: Application
    Filed: September 13, 2005
    Publication date: July 7, 2011
    Inventors: Andreas Bergmann, Joachim Struck
  • Publication number: 20110165651
    Abstract: The invention relates to reverse transcriptases which have increased fidelity (or reduced misincorporation rate) and/or terminal deoxynucleotidyl transferase activity. In particular, the invention relates to a method of making such reverse transcriptases by modifying or mutating specified positions in the reverse transcriptases. The invention also relates to nucleic acid molecules containing the genes encoding the reverse trancriptases of the invention, to host cells containing such nucleic acid molecules and to methods to make the reverse trancriptases using the host cells. The reverse transcriptases of the invention are particularly suited for nucleic acid synthesis, sequencing, amplification and cDNA synthesis.
    Type: Application
    Filed: April 22, 2010
    Publication date: July 7, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Robert Jason Potter, Kim Rosenthal
  • Publication number: 20110165602
    Abstract: Emission ratiometric indicators of phosphoinositides comprise a fusion protein comprising a pleckstrin homology (PH) domain of Akt (also known as protein kinase B) and a “pseudoligand” containing acidic amino acid residues, which is sandwiched between resonance energy transfer (RET) pairs, such as cyan and yellow mutants of GFP (a FRET pair). Such indicators can be used, inter alia, to monitor spatiotemporal dynamics of phosphoinositides and in high throughput assays for inhibitors of PI3K, including drug screening assays.
    Type: Application
    Filed: February 23, 2011
    Publication date: July 7, 2011
    Applicant: JOHNS HOPKINS UNIVERSITY
    Inventors: Jin Zhang, Bharath Ananthanarayanan
  • Publication number: 20110165653
    Abstract: The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors.
    Type: Application
    Filed: December 29, 2010
    Publication date: July 7, 2011
    Applicant: DARWIN MOLECULAR CORPORATION
    Inventor: MARGARET E BLACK
  • Publication number: 20110165652
    Abstract: Compositions, systems and methods of sequencing are disclosed, where the compositions and systems include polymerase enzymes that have been genetically modified to more efficiently incorporate nucleotides including labels having a detectable properties that are released during incorporation, to augment a rate of labeled nucleotide incorporation, to augment a rate of pyrophosphate release, or to augment two or more of these properties and rates. Also disclosed are terminally labeled and dual labeled nucleotides, and click-chemistry based methods of synthesizing the same.
    Type: Application
    Filed: January 14, 2009
    Publication date: July 7, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Susan H. Hardin, Tommie Lloyd Lincecum, JR., Norha Deluge, Hongyi Wang, Yuri Belosludtsev, Kristi Kincaid, Anelia Kraltcheva, Benjamin Stevens, Ming Fa, Amy Bryant, Amy Castillo, Hye Eun Kim, Uma Nagaswamy, Mitsu Sreedhar Reddy, Alok N. Bandekar, Ivan Pan, Andrei Volkov
  • Patent number: 7973131
    Abstract: The invention establishes a technology that allows non-specific amplification to be inhibited during nucleic acid amplification in an isothermal amplification reaction, such that the amplification efficiency is increased. The invention is a extreme thermophile single-stranded DNA binding mutant protein, having an amino acid sequence that expresses a function that can contribute to increasing an amplification efficiency of a template nucleic acid in an isothermal amplification reaction system that uses a strand displacement polymerase, and having in its amino acid sequence a mutation site where a mutation involving at least one of deletion, substitution, addition, and insertion of one or more amino acids in amino acid sequence of extreme thermophile single-stranded DNA binding protein has occurred, and a method of use thereof.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: July 5, 2011
    Assignees: Aisin Seiki Kabushiki Kaisha, Riken
    Inventors: Yasushi Shigemori, Takehiko Shibata, Tsutomu Mikawa
  • Patent number: 7973154
    Abstract: The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: July 5, 2011
    Assignee: TrovaGene, Inc.
    Inventors: Hovsep Melkonyan, Angela Cannas, Louis David Tomei, Samuil R. Umansky
  • Patent number: 7972830
    Abstract: It was found that a fragment of native Thermus aquaticus DNA polymerase (TaqWT) lacking 288 N-terminal amino acids (Taq?288) possesses an increased thermostability over TaqWT, Taq?279, and Taq?289. The present invention therefore provides Taq?288, recombinant expression vectors encoding the same or derivatives thereof, as well as purification protocols for Taq?288. The invention also encompasses kits containing Taq?288 as well as the use of Taq?288 and kits containing Taq?288. In addition, the invention encompasses methods for the sequencing a nucleic acid template and methods for amplifying a target nucleic acid.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: July 5, 2011
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Thomas Meier, Waltraud Ankenbauer, Annette Deufel, Dieter Heindl, Gisela Betzl, Rainer Schmuck, Bernd Schneidinger, Jessica Strey
  • Publication number: 20110160289
    Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.
    Type: Application
    Filed: May 3, 2010
    Publication date: June 30, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Mekbib ASTATKE, Deb K. Chatterjee, Gary F. Gerard
  • Publication number: 20110159568
    Abstract: The present invention relates to crystalline Mnk-1 and Mnk-2 kinases and, in particular, to the crystal structure of Mnk-1 and Mnk-2 kinase domain.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 30, 2011
    Inventors: Markus Wahl, Ralf Jauch, Kay Schreiter, Stefan Jäkel
  • Publication number: 20110162092
    Abstract: The present invention relates to a composition comprised of AKAP12 (A-Kinase anchoring protein 12) and to uses of AKAP12 mutant zebrafish as an animal model. More particularly, the following characteristics are noted in the present AKAP12 mRNA knockdown zebrafish: crooked or shortened tail, inability to move normally, non-uniform micro-vasculature in the brain, and change in heart shape with non-uniform and weak heartbeats. It also has various circulatory and genetic defects, such as hemorrhage from the ventricles of the heart, brain, and retina. All of these defects can be cured with AKAP12 injection. Therefore, AKAP12 can be used as an active component for a composition to prevent and heal circulatory and genetic defects that are caused by AKAP12 deficiency, and as a hemorrhage inhibitor. Further, the AKAP12 deficient mutant zebrafish can be useful as an animal model for verification of effectiveness of treatment for genetic defects in the circulatory system.
    Type: Application
    Filed: June 12, 2009
    Publication date: June 30, 2011
    Applicant: SNU RDB FOUNDATION
    Inventors: Kyu-Won Kim, Hyouk-Bum Kwon
  • Publication number: 20110159008
    Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
    Type: Application
    Filed: January 31, 2011
    Publication date: June 30, 2011
    Applicant: DELENEX THERAPEUTICS AG
    Inventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
  • Patent number: 7968309
    Abstract: A sucrose phosphorylase (SP) having improved thermostability obtained by modifying a natural SP and a method for producing the SP having improved thermostability is provided. This SP having improved thermostability has an amino acid residue which is different from that of the natural sucrose phosphorylase, in at least one position selected from the group consisting of a position corresponding to position 14, a position corresponding to position 29 and a position corresponding to position 44 in motif sequence 1; a position corresponding to position 7, a position corresponding to position 19, a position corresponding to position 23 and a position corresponding to position 34 in motif sequence 2; and a position corresponding to position 19 in motif sequence 3, and wherein the enzyme activity of the SP having improved thermostability at 37° C., after heating the SP having improved thermostability in 20 mM Tris buffer (pH 7.0) at 55° C.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: June 28, 2011
    Assignee: Ezaki Glico Co., Ltd.
    Inventors: Kazutoshi Fujii, Masae Iiboshi, Michiyo Yanase, Hiroki Takata, Takeshi Takaha, Takashi Kuriki
  • Patent number: 7968325
    Abstract: Coexpression of a polyhydroxyalkanoic acid synthase and a either a fatty acid:acyl-CoA transferase or an acyl-CoA synthetase in cells enables the biosynthesis of polyester materials. Plasmids, bacteria, materials, and methods for the preparation of polyesters are disclosed.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: June 28, 2011
    Assignee: Metabolix, Inc.
    Inventors: Silke Hein, Brigitte Sohling, Gerhard Gottschalk, Alexander Steinbuchel
  • Publication number: 20110150887
    Abstract: The invention relates to methods and compositions for regulation of GSK3? activity. The invention provides phosphorylated GSK3? polypeptides and antibodies that recognize such polypeptides. The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3? activity.
    Type: Application
    Filed: April 29, 2009
    Publication date: June 23, 2011
    Applicant: University of Vermont and State Agricultural College
    Inventors: Mercedes Rincon, Tina M. Thornton
  • Publication number: 20110152166
    Abstract: The present patent application discloses a method of identifying or validating a compound that modulates the phosphorylation-dependent activity of a target protein or protein complex, where the target protein or protein complex activity is regulated by phosphorylation, as well as the use of identified compounds for the production of a pharmaceutical preparation especially for the treatment of cancer, insulin resistance and diabetes.
    Type: Application
    Filed: August 20, 2007
    Publication date: June 23, 2011
    Inventors: Ricardo M. Biondi, Mathias Engel, Frodin Morten